

**Supplementary Table 1 Depiction of the PICO format used to construct the study question**

<b>Component</b>	<b>Description</b>
Population	Adult patients (18 years and older) with decompensated cirrhosis or advanced liver disease
Intervention	Measurement or use of NGAL biomarkers for assessing kidney function in patients with decompensated cirrhosis
Comparison	None (no specific intervention, or comparison to standard methods of assessing kidney function)
Outcome	Identifying the effectiveness and accuracy of biomarkers in assessing kidney function in patients with decompensated cirrhosis Secondarily, assessing the mortality in patients with decompensated cirrhosis

---

NGAL: Neutrophil gelatinase-associated lipocalin.

## Supplementary Table 2 Descriptive statistics for all the included studies

Total sample	3701 (21 studies)
Age	54.49 +- 8.34
Male	2591 (76%) (3 studies excluded)
Serum Creatinine	1.45 +- 0.65 (7 studies excluded)
INR	1.46+-0.41 (11 studies excluded)
MELD	19.04 +- 5.05 (1 study excluded)

INR: International normalized ratio; MELD: Model for End-Stage Liver Disease.